To view the clinical trial data of the following topics click here (pdf format)

Tyrosine kinase inhibitors in early chronic-phase CML

A. Robert Turner MD, FRCPC, Professor of Medicine, University of Alberta, and Cross Cancer Institute, Edmonton, AB

Cortes J, Baccarani M, Guilhot F et al. A Phase III, randomized, open-label study of 400 mg versus 800 mg of imatinib mesylate (IM) in patients (pts) with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) using molecular endpoints: 1-year results of TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) Study. ASH 2008, Abstract 335.

Cortes J, O’Brien S, Borthakur G et al. Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP). ASH 208, Abstract 182.

Rosti G, Castagnetti F, Poerio A et al. High and early rates of cytogenetic and molecular response with nilotinib 800 mg daily as first line treatment of Ph-Positive chronic myeloid leukemia in chronic phase: results of a phase 2 Trial of the GIMEMA CML Working Party. ASH 2008, Abstract 181.

Rituximab added to standard therapy in advanced chronic lymphocytic leukemia

Loree Larratt, MD, FRCPC, Clinical Hematologist, Alberta Health Services, Edmonton, AB

Hallek M, Fingerle-Rowson G, Fink A et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia. ASH 2008, Abstract 325.

Robak T, Moiseev S, Dmoszynska A et al. Rituximab, fludarabine, and cyclophosphamide (R-FC) prolongs progression free survival in relapsed or refractory chronic lymphocytic leukemia (CLL) compared with FC alone: final results from the international randomized Phase III
REACH Trial. ASH 2008, Abstract LBA-1.

Pentostatin replacing fludarabine in early chronic lymphocytic leukemia

Loree Larratt, MD, FRCPC, Clinical Hematologist, Alberta Health Services, Edmonton, AB

Reynolds C, Di Bella N, Lyons R et al. Phase III Trial of Fludarabine, Cyclophosphamide, and Rituximab Vs. Pentostatin, Cyclophosphamide, and Rituximab in B-Cell Chronic Lymphocytic Leukemia. ASH 2008, Abstract 327.

Flavopiridol in relapsed chronic lymphocytic leukemia

Loree Larratt, MD, FRCPC, Clinical Hematologist, Alberta Health Services, Edmonton, AB

T. Lin et al. Flavopiridol (Alvocidib) induces durable responses in relapsed chronic lymphocytic leukemia (CLL) patients with high-risk cytogenetic abnormalities. ASH 2008, Abstract 46.

To view the clinical trial data click here (pdf format)